#Sweden #Stockholm #Sobi #Gamifant #VEXAS

Sobi to Present New Clinical Data at EULAR 2025

Sobi®, officially known as Swedish Orphan Biovitrum, is set to showcase vital new clinical data during the upcoming European Congress of Rheumatology (EULAR 2025). This distinguished congress will occur from June 11 to June 14, 2025, in the vibrant city of Barcelona, Spain. The company is excited to present cutting-edge research outcomes related to its innovative treatments targeting severe rheumatological conditions.

Key Highlights of the Presentation

The forthcoming event will put the spotlight on several critical trials and studies:
1. Gamifant (emapalumab): An in-depth analysis of the efficacy and safety associated with Gamifant for patients grappling with macrophage activation syndrome (MAS) stemming from Still's disease. This pivotal oral presentation will be delivered by Professor Fabrizio De Benedetti, the principal investigator of the study, and is set for June 12. The results promise significant insights into treatment responsiveness in this challenging patient population.

2. Vonjo (pacritinib): Discussion surrounding the potential treatment options for VEXAS syndrome will be featured, alongside updates from ongoing trials. The formulation aims to address the debilitating symptoms experienced by those affected by this rare condition, with the focus on developing a consensus definition for VEXAS flare-ups utilized in future clinical research.

3. Uncontrolled Gout: Researchers will share findings on the discrepancies observed in the management of uncontrolled gout among rheumatologists and nephrologists, spotlighting barriers to effective treatment. This poster presentation scheduled for June 13 will be crucial for understanding therapeutic approaches and enhancing inter-specialty collaboration.

Additionally, Sobi will host an informative symposium on the dermatologic, rheumatologic, and hematologic aspects of VEXAS syndrome, which will be led by esteemed Dr. Sophie Georgin-Lavialle MD, PhD from the French National Reference Center for auto-inflammatory diseases. Continuing medical education at the symposium will encourage dynamic interactions, culminating in a panel discussion aimed at addressing pressing topics in the field.

Company Statements

Lydia Abad-Franch, MD, MBA, the Head of Research, Development, and Medical Affairs at Sobi, expressed her enthusiasm regarding the presentations:

"We are delighted that our continued advancements in treating rare diseases, including those suffering with the most debilitating rheumatology conditions, will be presented at this year's EULAR conference. Our presentations will provide insights and treatment options for those working with patients, ensuring they have access to the latest clinical data and methodologies."

Abad-Franch further emphasized the importance of collaboration in clinical research, stating,

"With multiple poster and oral presentations alongside an elaborate symposium, we look forward to rousing discussions that connect professionals in the field."

Notable Research Findings

The clinical data set for discussion includes a pooled analysis of trials indicating the effectiveness of emapalumab in addressing MAS in Still's disease. Notably, a significant portion of patients have shown inadequate responses to high-dose glucocorticoids, making the need for alternative therapies pressing.

Research into VEXAS syndrome, an emergent condition defined by mutations in the UBA1 gene, reveals dynamic presentations that necessitate focused medical attention due to their systemic and hematologic manifestations. Sobi aims to refine treatment protocols and enhance understanding through comprehensive research.

About Sobi

With a workforce of approximately 1,900 employees, Sobi has become a beacon of hope for those living with rare diseases. The company continues its trajectory of growth and innovation within the pharmaceutical landscape, guided by its mission to unlock the potential of breakthrough treatments. For further information on Sobi and its contributions to rheumatological care, visit sobi.com.

As the EULAR 2025 conference approaches, anticipation builds around Sobi's groundbreaking findings and the contributions these treatments can make towards improving quality of life for vulnerable patient populations.